home Transpl Infect Dis Clinical experience with the use of novel cephalosporin/beta-lactamase inhibitor combinations among solid organ transplant recipients.

Clinical experience with the use of novel cephalosporin/beta-lactamase inhibitor combinations among solid organ transplant recipients.

Related Articles

Clinical experience with the use of novel cephalosporin/beta-lactamase inhibitor combinations among solid organ transplant recipients.

Transpl Infect Dis. 2019 Aug 16;:e13161

Authors: Nambiar PH, Brizendine KD, Athans V, Cober E

Abstract
SOT recipients are at increased risk of infection due to multidrug-resistant (MDR) organisms including carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa. Ceftazidime/avibactam (C/A) possesses activity against Klebsiella pneumoniae carbapenemase and OXA-48-like carbapenemase-producing Enterobacteriaceae. Ceftolozane/tazobactam (C/T) is active against MDR P. aeruginosa. The present study characterized outcomes of SOT recipients treated for CRE and MDR P. aeruginosa with C/A or C/T. This article is protected by copyright. All rights reserved.

PMID: 31419340 [PubMed - as supplied by publisher]